检索结果-南通市图书馆

Envita’s Precision Cancer Care: 35-Fold Improvement in Response Rates

Journal of Cancer Therapy 2024年第4期15卷 99-120页

作者： Sheba Goklany John C. Oertle III Ronald Matthias Jr. Daniel Warren David Medina Rory Sears Robert Zieve Kendra Quart Christopher Aussems Jon Moma Shannon Miller Zach Poteet Conner Coffin Courtney Middleton Erika Ware Phylicia Zarnosky Julie Nowak Winlove Suasin Daniel Conway Chad Burk Ruth Tan-Lim Dino Prato Envita Medical Centers Scottsdale AZ USA

New clinical approaches are imperative beyond the widely adopted National Comprehensive Cancer Network (NCCN) guidelines, utilized by prominent cancer institutions. Cancer is the leading cause of death among individuals younger than 85 years within the United States. Despite significant technological advances, including the expenditure of hundreds of billions, treatment outcomes and overall survival have not notably improved for most types of advanced cancer over the last several decades. Over the past 24 years, Envita Medical Centers has pioneered a unique form of personalized treatment approach for late-stage and refractory cancer patients, introducing groundbreaking innovations in the field. Our integrated algorithm utilizes advanced genomics, transcriptomics, and highly tailored immunotherapy, resulting in remarkable outcome improvements. This study presents Envita’s innovative personalized treatment algorithms and examines the response outcomes of 199 late-stage cancer patients treated at Envita Medical Centers over a two-year period. Compared to standard of care and palliative chemotherapy, Envita’s treatment demonstrated a remarkable 35-fold improvement in overall response rates (Figure 1). Moreover, 88% of the patients, the majority presenting with Stage 3 or 4 cancer, experienced a 43-fold improvement in quality of life with minimal side effects, as compared to standard of care chemotherapy and palliative care. This revolutionary success is attributed to Envita’s personalized therapeutic algorithms, which incorporate customized immunotherapy. Envita’s precision care approach has also achieved a 100% better response rate compared to over 65 global chemotherapy clinical trials with more than 2700 patients. The results from this study suggest that a wider utilization of Envita’s personalized approach can significantly benefit patients with late-stage and refractory cancer.

关键词： Envita Medical Centers Late-stage Cancer Overall Response Rate Quality of Life Circulating Tumor Cells (CTCs) Mutant Allele Frequency (MAF) Precision Care

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chronic Lyme Disease: Persistent Clinical Symptoms Related to Immune Evasion, Antibiotic Resistance and Various Defense Mechanisms of <i>Borrelia burgdorferi</i>

引用

Open Journal of Medical Microbiology 2014年第4期4卷 252-260页

作者： Aaron J. Smith John Oertle Dino Prato Envita Scottsdale AZ USA

There are several factors involved in the ability of Borrelia burgdorferi to retain a persistent infection within a mammalian host. These factors of immune evasion include regulation of membrane proteins, variable epitopes of surface proteins, protection against the immune system through tick saliva, the ability to migrate to regions where it is not exposed to the immune system or antibiotics, invagination or invasion within various cells, pleomorphic forms, and the potential to produce biofilms. The window of conventional treatment for Lyme disease is short and has the potential to display different symptoms depending on the strain of Borrelia bugdorferi. These symptoms are dependent on the localization of Borrelia burgdorferi which correlates to the significance of diagnosing Lyme disease early to prevent such a spread throughout the body. Such complications of Borrelia burgdorferi may demand new clinical treatment discoveries for patient fighting the chronic form.

关键词： Borrelia burgdorferi Immune Response Antibiotics Surface Proteins Pleomorphism Ixode Tick

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer and Infectious Causes

引用

Open Journal of Medical Microbiology 2014年第3期4卷 161-177页

作者： Aaron J. Smith John Oertle Dino Prato Envita Scottsdale AZ USA

Various kinds of organisms, including viruses, bacteria, trematodes and fungi are known carcinogens that cause cancer. Infectious identification related to cancer may lead to better treatment for both the prevention and targeting of cancer therapy. Although nearly 20% of all cancers are caused by an infection of a microbe, the amount of evidence and information regarding the mechanisms associated with oncogenesis varies dramatically from one organism to the next. This review cannot be exhaustive because we are not aware of all infections worldwide in addition to their potential mechanisms for oncogenesis. More research is required for all of the species mentioned in this review.

关键词： Epstein Bar Virus Hepatitis B Virus Hepatitis C Virus Human Herpes Virus 6 Human Herpes Virus 8 Human Papillomavirus Human T-Cell Leukemia Virus Type 1 Merkel Cell Polyomavirus Chlamydia pneumonia Helicobacter pylori Mycoplasma Salmonella typhi-1 Streptococcus bovis Clonorchis sinensis Opisthorchis viverrini Schistosoma haematobium Aspergillus flavus Aspergillus parasiticus Cancer Oncogenesis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Immunotherapy in Cancer Treatment

引用

Open Journal of Medical Microbiology 2014年第3期4卷 178-191页

作者： Aaron J. Smith John Oertle Dino Prato Envita Scottsdale AZ USA

Various kinds of immunotherapy treatment for cancer are either available to the public or are in the process of clinical trials. Immunotherapy treatments have the potential to treat cancer with significantly less toxicity than chemotherapy and radiation treatments. An emphasis on cellular infusion as a method of either enhancing the immune system by creating an environment for sequestering the host immune system to attack cancer cells or more directly inserting cells to directly attack cancer cells will be provided in this review. Various forms of cancer vaccines are also discussed in this paper as an important aspect in immunotherapy. This review seeks to describe various methodologies associated with administering immunotherapy in the treatment of cancer.

关键词： Immunotherapy Cancer T-cell NK Cell Dendrite CIK Nano Particles Exosomes

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Autologous Natural Killer Cell/Natural Killer T Cell Immunotherapy of Malignant Diseases

引用

Open Journal of Medical Microbiology 2014年第3期4卷 192-202页

作者： Aaron J. Smith John Oertle Dino Prato Envita Scottsdale AZ USA

Adoptive immunotherapy, the therapeutic infusion of ex vivo activated cancer-fighting white blood cells that was pioneered by Dr. Steven Rosenberg over 30 years ago, has become more widespread due to outstanding published research documenting the clinical efficacy of this strategy. Based on the well-established in vivo functions of NK and NKT cells, their integral role in the efficacy of certain chemotherapeutic and immunomodulatory agents, and their direct therapeutic action as displayed in clinical trials, the use of autologous natural killer cell infusions is an appropriate and warranted therapeutic option for the treatment of malignant diseases, especially in patients whose disease is refractory to standard treatments such as chemotherapy and radiation.

关键词： Cancer Immunotherapy Autologous Natural Killer Cells (NK Cells) Natural Killer T Cell (NKT Cells) Lymphocyte Activated Killer Cells (LAK cells)

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

COVID-19 Patient with Multifocal Pneumonia and Respiratory Difficulty Resolved Quickly: Possible Antiviral and Anti-Inflammatory Benefits of Quercinex (Nebulized Quercetin-NAC) as Adjuvant

引用

Advances in Infectious Diseases 2020年第3期10卷 45-55页

作者： Robert Schettig Trevor Sears Matthew Klein Ruth Tan-Lim Ronald Matthias Jr. Christopher Aussems Michael Hummel Rory Sears Zachary Poteet Daniel Warren John Oertle Dino Prato Envita Medical Center Scottsdale USA

Background: SARS-CoV-2 (COVID-19) is a viral pandemic with no current vaccine or effective treatment. Hydroxychloroquine and azithromycin are not without cardiovascular risk or complications, and these treatments can fail to aid in full recovery from COVID-19. As new treatments become approved for the pandemic, an inexpensive, non-toxic, and safe adjunctive therapy is needed. Case Presentation: A 59-year-old male presented with respiratory symptoms. Chest X-ray revealed classic indications of COVID-19 pneumonia. A PCR nasopharyngeal swab test confirmed a COVID-19 infection and hospital doctors prescribed Rocephin, azithromycin, and hydroxychloroquine. The patient was then prescribed Quercinex, a nebulized formula of quercetin-(cyclodextrin) (20 mg/mL) and N-acetylcysteine (100 mg/mL) three times daily for 14 days by physicians at Envita Medical Center for continued COVID-19 respiratory symptoms. Following 30 minutes after each nebulization treatment, the patient experienced immediate deep breathing relief that lasted for multiple hours. Within the following 48 hours after the first treatment, respiratory symptoms continued to diminish and resolve quickly. Finally, post-treatment follow-up chest X-rays revealed no pulmonary fibrosis (scarring) and clear lung fields. Conclusion: The Quercinex formula appeared to greatly alleviate the unresolved respiratory symptoms rapidly. Several mechanisms of the formula, namely antiviral and anti-inflammatory action, with direct administration via nebulizer to the deep lung tissue, could potentially explain the fast and complete recovery. We recommend that the Quercinex formula be considered for further clinical study as an adjuvant or on its own for COVID-19 and possibly other viral pulmonary conditions.

关键词： Quercetin N-Acetylcysteine (NAC) SARS-CoV-2 (COVID-19) Quercinex Envita Zinc Pneumonia Case Study Severe Acute Respiratory Syndrome Flavonoid Lung Antiviral Human

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Melatonin: A Powerful Integrative Adjunctive Agent for Oncology

引用

Journal of Cancer Therapy 2020年第9期11卷 571-596页

作者： Robert Schettig Trevor Sears Matthew Klein Ruth Tan-Lim Ronald Matthias Christopher Aussems Michael Hummel Rory Sears Zachary Poteet Daniel Warren John Oertle Connor Coffin Dino Prato Envita Medical Center Scottsdale AZ USA

Melatonin is an established hormone supplement and has been well recognized for its effect on the circadian cycle to improve sleep, REM (rapid eye movement), and aiding in jetlag recovery. The utility of melatonin extends beyond sleep aid, however. This hormone also possesses less well-known antioxidant action and even robust anticancer activity. Melatonin may be a key supplement for addressing age-related neurologic decline while serving as a valuable adjunctive cancer treatment that reduces drug resistance in tumors and downregulates angiogenesis. In immunotherapy, melatonin activates Natural Killer (NK) cells nested within tumoral tissue and does not have the side effect profile of other immunoreactive agents used for chemotherapy. Since melatonin is found in high concentrations in the brain and other hormone-linked tissues, the relevance of melatonin is increased for the treatment of estrogen-linked cancers. The immunomodulatory effect of melatonin may also help with chronic inflammation seen in patients with autoimmune disorders. All of these effects together represent a unique and versatile therapeutic agent for integrative medicine. No other commercially available drug possesses all of these therapeutic mechanisms while having a very minimal side effect profile and being considered overall to be safe to use. Currently, melatonin is underutilized in medicine, especially in the field of integrative oncology and represents a crucial supportive adjuvant to improve the lives of patients.

关键词： Melatonin Oncology Immunotherapy Chronic Inflammation Autoimmune Envita Antioxidant Anticancer Antiangiogenesis Telomerase Metastasis Anti-Proliferation Pro-Apoptosis Immune System Activation Cancer Adjuvant Chemotherapy Synergy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

PathoDNA, an Advanced Diagnostic for Lyme Disease &Co-Infections Utilizing Next Generation DNA Sequencing with Greater Sensitivity and Selectivity than ELISA/Western Blot

引用

Advances in Infectious Diseases 2021年第4期11卷 405-429页

作者： Robert Schettig Ruth Tan-Lim Daniel Warren Zachary Poteet Rory Sears Michael Hummel Connor Coffin Kendra Quart Christopher Aussems Ronald Matthias Jr. David Medina Matthew Klein Gayle Roberts John C. Oertle III Dino Prato Envita Scottsdale USA

The controversial subject of chronic Lyme disease has occupied medical discourse for years while contributing to unprecedented patient suffering in the United States and abroad. A general misunderstanding of Lyme disease and overconfidence in the Center for Disease Control’s (CDC) recommended two-step test for Lyme disease has led to misdiagnosis and incorrect treatment over the years. This leads to increasing medical expenses and worse outcomes for patients. The two-step test, an ELISA immunoblot followed by a confirmatory Western blot, yields accuracy rates as low as 29% for acute Lyme disease and 75% for chronic Lyme disease. While these practices have been a staple of microbiology for decades, these accuracy rates are unacceptable for diagnostic tests when better technology is available. PathoDNA, a Next-Generation DNA sequencing test for Lyme disease and other tick-borne pathogens, achieves accuracy rates of 98% for B. burgdorferi and 95% or greater for other common tick-borne pathogens with superior sensitivity and selectivity. PathoDNA is a Clinical Laboratory Improvement and Amendments (CLIA)-validated laboratory test that achieves these results utilizing Next Generational DNA Sequencing and a proprietary bioinformatics database. Thus, it allows for rapid results and specific identification of tick-borne illnesses. In this article, we will compare this promising technology against the existing standards for diagnosing and testing Lyme disease. We believe that PathoDNA can set a new standard for identifying Borrelia and diagnosing Lyme disease along with other tick-borne infections.

关键词： Lyme Disease Ticks Tick-Borne Borrelia Sequencing Diagnosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Multiple Actions of Curcumin Including Anticancer, Anti-Inflammatory, Antimicrobial and Enhancement via Cyclodextrin

引用

Journal of Cancer Therapy 2015年第3期6卷 257-272页

作者： Aaron J. Smith John Oertle Dino Prato Envita Scottsdale USA

Curcumin is a naturally occurring phytotherapeutic that has broad uses including the treatment of cancer and as a potent antimicrobial agent. Its dynamic ability to treat very different kinds of disease has spawned a significant increase in inquiry on how curcumin accomplishes these feats. Thousands of peer reviewed papers were published in the past few years regarding the various functions of curcumin. Unlike most pharmaceuticals, curcumin has a multi-range of different targets that it interacts with. Since curcumin’s bioavailabilty is limited, methods of increasing curcumin’s bioavailabilty are discussed. Mechanisms of action regarding curcumin’s ability to effect cancer are discussed including upstream and downstream mechanisms starting with epigenetics to its effect on signal transduction pathways and apoptosis. Curcumin also works adjuvantly with chemotherapy to reduce resistance and enhance the mechanism of certain chemotherapeutic agents. Curcumin’s antibacterial, antifungal, and antiviral capability is also discussed with regard to curcumin’s dynamic ability to treat infections. Curcumin use in cancer adjunctive care and its anti-infectious capabilities make it a unique phytotherapeutic agent with promise.

关键词： Curcumin Cancer Chemotherapy Anti-Inflammatory Antimicrobial Cyclodextrin

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Novel Approach to Chemotherapy and Administration Selection with Metronomic/Fractionated Dosing

引用

Journal of Cancer Therapy 2015年第5期6卷 455-465页

作者： Aaron J. Smith John Oertle Dino Prato Envita Scottsdale AZ USA

Metronomic dosing of chemotherapy was introduced in the early 2000s and has since gained recognition as a potential game changer in the manner of which chemotherapy can be administered. There are several known candidates for metronomic dosing of chemotherapy with the potential for many more to be elucidated in the future. Minimized overall side effects, longer durations of treatment, potential minimization of multidrug resistance (MDR) mutations, potential less refractory responses, and the potential to safely use more than one chemotherapy treatments also make metronomic dosing of chemotherapy attractive. Metronomic dosing reduces common side effects and has the potential to reduce neutropenia, lymphocytopenia, and cognitive changes associated with maximum tolerated dosages (MTD). Methods of enhancing chemotherapy including fasting and administration of insulin are also discussed. Metronomic dosing combined with a patient’s molecular profile derived from biomarkers is particularly exciting. It holds significant potential with regard to administrating the most relevant chemotherapies and offers maximal beneficial results.

关键词： Metronomic Dosing Chemotherapy Multidrug Resistance Neutropenia Lymphocytopenia Insulin Biomarkers Cognitive Changes

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：